Core Viewpoint - Semler Scientific, Inc. has seen a significant increase in stock value, rising over 130% in November due to its strategic pivot towards Bitcoin investments, introducing "Bitcoin Yield" as a key performance indicator [1][2] Company Overview - Semler Scientific specializes in healthcare technology solutions aimed at improving clinical efficiency for healthcare providers in the U.S. [2][3] - The company's flagship product, QuantaFlo, is a diagnostic tool for evaluating vascular health, while it also offers Insulin Insights for optimizing insulin dosing [3] Bitcoin Investment Strategy - In November, Semler increased its Bitcoin holdings by purchasing 215 Bitcoin for $17.7 million, raising its total to 1,273 Bitcoin at an average acquisition price of nearly $69,700 [4][5] - This acquisition was partially funded through an at-the-market stock offering that generated $21.5 million by selling 505,544 shares [4] Financial Performance - Semler's Q3 earnings report showed diluted EPS of 72 cents, exceeding the forecast of 48 cents, largely due to $1.1 million in unrealized gains from Bitcoin [6] - However, revenue declined to $13.5 million in Q3 from $16.3 million in the same period last year, indicating challenges in its core business [7][8] Market Position and Speculation - Semler's embrace of Bitcoin has positioned it as a speculative favorite among investors, similar to other crypto-related stocks, although it remains primarily a healthcare company [2][5] - The company's pivot to Bitcoin may be a strategy to diversify earnings and attract investor interest amid declining revenues in its core business [8] Risks and Challenges - The volatility of Bitcoin presents a risk to Semler's earnings, especially given the reliance on unrealized gains that have supported recent financial results [10] - The core business continues to face challenges, including declining revenues and limited customer base expansion [10]

The medical device company has made a peculiar bet on a popular cryptocurrency.Semler Scientific (SMLR -2.31%) shot up 24.5% in October, according to data from S&P Global Market Intelligence. The medical device company has started buying up Bitcoin with cash on its balance sheet, which is correlating its stock price to the popular cryptocurrency. Even after the price jump last month, the stock is still down 35.4% in the last five years as it saw slowing revenue and declining operating margins.Here's why Sem ...

SANTA CLARA, Calif., Oct. 21, 2024 /PRNewswire/ -- Semler Scientific, Inc. (Nasdaq: SMLR), a pioneer in developing and marketing technology products and services to healthcare providers to combat chronic diseases, today announced that it will report financial results for the third quarter and nine months ended September 30, 2024, as well as provide an update on its Bitcoin holdings after the close of U.S. financial markets on Monday, November 4, 2024. Doug Murphy-Chutorian, M.D., chief executive officer of ...

SANTA CLARA, Calif., Aug. 26, 2024 /PRNewswire/ -- Semler Scientific, Inc. (Nasdaq: SMLR), a pioneer in developing and marketing technology products and services to healthcare providers to combat chronic diseases, today announced that it has purchased an additional 83 bitcoins for $5.0 million in cash, inclusive of fees and expenses. As of August 26, 2024, Semler Scientific holds a total of 1,012 bitcoins, which were acquired for $68.0 million, inclusive of fees and expenses. "We recently purchased addition ...

SANTA CLARA, Calif., July 22, 2024 /PRNewswire/ -- Semler Scientific, Inc. (Nasdaq: SMLR), a pioneer in developing and marketing technology products and services to healthcare providers to combat chronic diseases, today announced that it will report financial results for the second quarter and six months ended June 30, 2024, after the close of U.S. financial markets on Monday, August 5, 2024. Doug Murphy-Chutorian, M.D., chief executive officer of Semler Scientific, will host a conference call at 4:30 pm ET ...

Core Insights - Semler Scientific, Inc. has purchased an additional 247 bitcoins for a total of $17 million, bringing its total holdings to 828 bitcoins acquired for an aggregate of $57 million [2][5] - The company is focused on expanding its healthcare business and acquiring bitcoin as a primary treasury reserve asset, viewing bitcoin as a compelling investment and reliable store of value [8] Company Overview - Semler Scientific develops and markets innovative products to combat chronic diseases, with its flagship product being QuantaFlo®, a rapid point-of-care test for measuring arterial blood flow [6] - QuantaFlo® is FDA-cleared and aids in diagnosing cardiovascular diseases, and the company is seeking new 510(k) clearance for expanded indications [6] Investment Strategy - The company has adopted a strategy of purchasing bitcoins with cash, emphasizing its commitment to this approach as part of its overall business strategy [8]

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___ to ___ Commission File Number: 001-36305 SEMLER SCIENTIFIC, INC. Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 or Indicate by check mark whether the registrant (1) has filed all reports required t ...

Financial Data and Key Metrics - Total revenues in Q1 2024 were $15.9 million, a decrease of 13% compared to Q1 2023 [5] - Fixed fee revenues were $7.1 million, a decrease of 24% year-over-year [5] - Variable fee revenues were $8 million, a decrease of 6% year-over-year [5] - Equipment and other revenues were $0.8 million, an increase of 140% year-over-year [33] - Operating expenses in Q1 2024 were $8.9 million, a decrease of 25% year-over-year, representing 56% of revenues compared to 66% in 2023 [6] - Pretax net income was $7.8 million compared to $6.6 million in the prior year [7] - Net income was $6.1 million or $0.88 per basic share and $0.78 per fully diluted share, compared to $5 million or $0.74 per basic share and $0.63 per fully diluted share in Q1 2023 [7] - Cash balance at March 31, 2024, was a record high of $62.9 million [7] Business Line Data and Key Metrics - The company's revenues are driven by sales of QuantaFlo for testing peripheral arterial disease (PAD) [5] - The three largest customers, including their related affiliates, comprised 45%, 25%, and 11% of quarterly revenue [6] - The company is pursuing an additional 510(k) clearance from the FDA for QuantaFlo to broaden its utility for a wider array of cardiovascular diseases, with anticipated clearance in the second half of 2024 [8][40] Market Data and Key Metrics - The Centers for Medicare and Medicaid Services (CMS) announced the three-year phase-in of the removal of the HCC code relating to PAD without complications from the Medicare Advantage risk adjustment model, with 2024 being the first year of the phase-in [11] - The company expects revenues in 2024 to follow a similar cadence to 2023, with H1 more heavily weighted than H2 [11][44] Company Strategy and Industry Competition - The company is focused on expanding its customer base for PAD and exploring inorganic growth initiatives to diversify its product portfolio [17][49] - The company is committed to research and development to enhance existing products and data services, with a long-term vision of extending its reach to additional cardiovascular applications [36] - The company aims to establish QuantaFlo as the standard of care for PAD diagnosis and diversify its customer base by adding new medical centers and expanding within value-based care providers and the VA system [35] Management Commentary on Operating Environment and Future Outlook - The company achieved year-over-year earnings growth despite a regulatory-driven revenue decline from its PAD product [2] - The company anticipates a slight uptick in expenses as it prepares for the next phase of launching QuantaFlo with expanded use [12] - The company is encouraged by the continued testing for PAD, given the importance of early diagnosis and treatment [11] - The company believes its technology can play a central role in delivering healthier outcomes for patients and substantial economic value to customers [15] Other Important Information - The company has a $20 million share buyback authorization, with $5 million already repurchased and $15 million remaining [45] Q&A Session Summary Question: Timing and process for receiving the 510(k) clearance - The company anticipates receiving clearance in the second half of 2024 and will start marketing the expanded use of QuantaFlo to existing customers upon approval [40][50] Question: Current demand environment and potential customer loss - The company has seen continued testing for PAD but also some cleanup of underutilized units. The clinical value of testing remains the same, and the company has a robust pipeline for growth [23][24] Question: Potential uses of cash for inorganic growth opportunities - The company is exploring inorganic growth initiatives, including strategic partnerships and acquisitions, to diversify its product portfolio [17][51] Question: Revenue cadence for 2024 - The company expects revenues to follow a similar cadence to 2023, with H1 more heavily weighted than H2 [44] Question: Specific conditions QuantaFlo might identify with the 510(k) clearance - The expanded use of QuantaFlo will focus on heart dysfunction, with specific wording to be released upon FDA clearance [41]

Exhibit 99.1 Semler Scientific® Reports First Quarter 2024 Financial Results 2024 Q1 highlights compared to the corresponding period of 2023: Santa Clara, CA – May 7, 2024 – Semler Scientific, Inc. (Nasdaq: SMLR), a company that develops, manufactures and markets innovative medical products and services that assist in evaluating and treating chronic diseases, today reported financial results for the first quarter ended March 31, 2024. "We had a very strong quarter of cash generation despite the regulatory-d ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended: December 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from: to Commission file number: 001-36305 SEMLER SCIENTIFIC, INC. (Exact name of registrant as specified in its charter) Delaware 26-1367393 (State or other ju ...